Regentis Biomaterials

Historical price data

Regentis Biomaterials' mission is to develop and commercialize innovative, hydrogel-based biomaterial implants that facilitate the body's natural healing process for damaged cartilage and bone. Its key achievement is the CE Mark and Israeli approval of GelrinC for focal cartilage defects, validating its core technology platform. The company's strategy involves leveraging this platform to expand into adjacent orthopedic indications, such as bone repair with GelrinB, while seeking commercial partnerships and regulatory approvals in key global markets like the United States. Its focus remains on providing standardized, scalable alternatives to complex biological procedures.

A proprietary synthetic hydrogel platform based on polyethylene glycol (PEG) and fibrinogen-derived peptides, which is applied as a liquid and photopolymerized in-situ to form a biodegradable scaffold that degrades enzymatically in sync with new tissue growth.

Regentis competes with established cell-based therapies (Vericel) and allografts in cartilage repair, and major medtech players (Stryker, Medtronic) in bone grafts. Its key differentiator is its synthetic, in-situ curing hydrogel that offers handling advantages and a degradation profile matched to tissue healing.